Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating the Efficacy of Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Phase of Trial: Phase II
Latest Information Update: 26 May 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 14 Feb 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 14 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
- 02 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.